Tenax Therapeutics(TENX)

Focus: Tenax Therapeutics is a newly public (2024) cardiovascular-focused biotech developing small-molecule therapeutics for pulmonary hypertension, heart failure, and traumatic brain injury. The company is in early-to-mid stage clinical development with no marketed products.

Cardiovascular

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Tenax Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Tenax Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

Levosimendan

Heart Decompensation

N/A

Clinical Trials (1)

NCT02973620Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure

N/A

Help build intelligence for Tenax Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Entry-stage public company with access to capital markets—FY2025 R&D budget expanded 4.3x to $13M, signaling commitment to pipeline advancement
Focused cardiovascular portfolio with 4 Phase 3 programs offers clear clinical development trajectory and visibility into near-term regulatory catalysts
Chapel Hill location provides access to biotech ecosystem and potential academic partnerships

Watch Out For

Currently zero open positions; company appears in stealth/consolidation mode post-IPO, limiting immediate hiring opportunities
Burn rate accelerating ($17.6M net loss in FY2025) while cash position modest at $95M—runway concerns if Phase 3 trials disappoint or extend
Pre-revenue biotech with no approved products creates execution risk; career progression depends entirely on pipeline success

Generated by Claude from Tenax Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Oxycyte

Traumatic Brain Injury

PHASE_2

Clinical Trials (1)

NCT00174980Study of Oxycyte in Severe Closed Head Injury

Phase 2

Oxycyte

Traumatic Brain Injury

PHASE_2

Clinical Trials (1)

NCT00908063Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)

Phase 2

Levosimendan

Hypertension Pulmonary Secondary

PHASE_2

Clinical Trials (1)

NCT03541603Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Phase 2

Levosimendan 2.5 mg/ml Injectable Solution

Hypertension Pulmonary Secondary Heart Failure

PHASE_2

TNX-103

Pulmonary Hypertension Associated With HFpEF

PHASE_3

Clinical Trials (1)

NCT07436689Long-Term Open-Label Extension Study of Oral Levosimendan

Phase 3

TNX-103

Pulmonary Hypertension

PHASE_3

TNX-103

Pulmonary Hypertension Associated With HFpEF

PHASE_3

Clinical Trials (1)

NCT07288398LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Phase 3

Levosimendan

Coronary Artery Bypass Grafting

PHASE_3

Clinical Trials (1)

NCT02025621Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 7 clinical trials

Top TAs: Cardiovascular

Publications: 6 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Cardiovascular

4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$13M294%

Net Income

-$18M

Cash

Research Publications(6)

Recent peer-reviewed publications with author affiliations at this company

Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial.

Journal of cardiac failure

2025

PMID:40633684

My Quest for Calcium Channel Blockers as the First Medical Treatment for Patients With Pulmonary Hypertension.